Tempus AI To Acquire Personalis for $1.5 Billion

Personalis, Inc. (PSNL) entered a merger agreement on July 20, 2026, to be acquired by Tempus AI, Inc. (TEM) in a deal valued at $1.5 billion.

Deal Structure:

Personalis shareholders will receive consideration of $16.25 per share of common stock, representing a premium of 5.59% from the stock’s last close.

Personalis shareholders will receive a floating exchange ratio of Tempus AI common stock at closing, subject to a maximum exchange ratio of 0.3356.

The transaction will be structured as an all-stock deal, with Tempus retaining the option to pay up to 50% of the total consideration in cash at its discretion.

Company Profile:

Personalis is a cancer genomics company that develops genomic testing solutions for cancer diagnosis, treatment selection, and disease monitoring. The company provides tumor profiling and minimal residual disease (MRD) testing services to biopharmaceutical companies, healthcare providers, and research institutions.

Tempus AI is a healthcare technology company that develops AI-enabled precision medicine solutions for cancer and other diseases. The company provides genomic testing, clinical data analytics, and software platforms that support diagnosis, treatment selection, clinical research, and drug development.

Deal Details and Timeline:

The acquisition expands Tempus’ capabilities in MRD testing and enables the company to support patients throughout their care, from diagnosis and treatment selection to disease monitoring and recurrence detection.

The acquisition builds on the companies’ existing partnership, which began in November 2023 when Tempus invested in Personalis and started commercializing its NeXT Personal MRD test.

The acquisition combines Tempus’ AI and precision oncology platform with Personalis’ tumor-informed MRD technology to improve cancer monitoring, support biomarker discovery, and strengthen personalized cancer care.

The consideration will be funded through cash on hand and borrowings under the company’s existing credit facilities.

The merger is anticipated to be finalized in late 2026 or early 2027.

Tempus is paying 22.29 times the sales for Personalis.

Deal Metrics:

For more in-depth insights regarding this M&A transaction, you can refer to the Deal Metrics page here:
Deal Metrics for the acquisition of Personalis, Inc. (PSNL) by Tempus AI, Inc. (TEM)

The Deal Metrics page offers a comprehensive view of the merger or acquisition, including:

• An extensive spread history of the merger from announcement to completion or termination.
• A timeline detailing every event such as the expiration of the HSR period, regulatory approvals, shareholder votes, and more.
• Access to relevant news and SEC filings.
• A history of deal updates.
• And many more insights.

Disclaimer: This article is for informational purposes only. Please conduct your own research and due diligence before making any investment decisions based on the content or data provided herein. We do not guarantee the completeness or accuracy of the information in this article.

Editor’s Note: Baranjot Kaur contributed to this article